Orion Corporation
Finnish pharmaceutical company
Nasdaq Helsinki
ISIN FI0009014377 LEI 74370029VAHCXDR7B745
Follow Orion
Weekly email: filings, results
Revenue, last year
€1.9B
+22.5% vs prior year
Net income
€500.3M
+51.7% vs prior year
EPS, diluted
€3.56
+51.5% vs prior year
Operating cash flow
€316.8M
+8% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €1.9B | €500.3M |
| FY24 | €1.5B | €329.9M |
| FY23 | €1.2B | €216.8M |
| FY22 | €1.3B | €349.5M |
| FY21 | €1B | €193.8M |
| FY20 | €1.1B | €219.9M |
| FY19 | €1.1B | €200.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 64.2% | 33.4% | 26.5% |
| FY24 | 61.4% | 27% | 21.4% |
| FY23 | 55.3% | 23.1% | 18.2% |
| FY22 | 63.3% | 32.8% | 26.1% |
| FY21 | 57% | 23.4% | 18.6% |
| FY20 | 60.4% | 26% | 20.4% |
| FY19 | 60.3% | 24.1% | 19.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | €243.4M |
| FY24 | €231.1M |
| FY23 | €53.4M |
| FY22 | €377.9M |
| FY21 | €168.7M |
| FY20 | €265.1M |
| FY19 | €242.1M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | €231.1M | - |
| FY24 | €228M | €0 |
| FY23 | €224.9M | - |
| FY22 | €211.2M | €17.9M |
| FY21 | €211.2M | - |
| FY20 | €211.1M | - |
| FY19 | €211.2M | €7.4M |
- Orion
- Healthcare median
Show the numbers
| Year | Orion | Healthcare median |
|---|---|---|
| FY25 | 26.5% | −30.6% |
| FY24 | 21.4% | −47% |
| FY23 | 18.2% | −58% |
| FY22 | 26.1% | −80.4% |
| FY21 | 18.6% | −71.9% |
| FY20 | 20.4% | −62.2% |
| FY19 | 19.1% | −46.3% |